Wetzel Investment Advisors Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,309 shares of the company’s stock after selling 139 shares during the period. Wetzel Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $715,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the company. MRP Capital Investments LLC increased its stake in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after purchasing an additional 65 shares in the last quarter. Syverson Strege & Co increased its stake in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after purchasing an additional 65 shares in the last quarter. Denali Advisors LLC increased its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after purchasing an additional 67 shares in the last quarter. Sage Mountain Advisors LLC increased its stake in Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after purchasing an additional 67 shares in the last quarter. Finally, Sovereign Financial Group Inc. increased its stake in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $152.27 on Wednesday. The company’s fifty day moving average price is $153.99 and its 200 day moving average price is $153.68. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market capitalization of $366.36 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 2.29 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.42%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Barclays cut their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.88.
Read Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- How to buy stock: A step-by-step guide for beginners
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- How to Short Nasdaq: An Easy-to-Follow Guide
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- How to invest in marijuana stocks in 7 steps
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.